Literature DB >> 9596001

Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study.

G E Tietjen1, M Day, L Norris, S Aurora, A Halvorsen, L R Schultz, S R Levine.   

Abstract

Anticardiolipin antibodies (aCL) are a risk factor for cerebral ischemia. In migraine, the association is controversial, with widely varying results in different small series. The controversy in part may be due to the inherent difficulty in distinguishing the transient focal neurologic events (TFNE) of migraine from TIA. To assess the frequency of aCL in migraine, we prospectively evaluated consecutive adults under 60 years of age with migraine without aura and with recent TFNE (<24-hour duration) clinically suggestive of either migraine with aura or TIA. We concomitantly enrolled persons with no CNS disease. Each person was interviewed and had blood drawn for solid-phase ELISA with IgG and IgM aCL isotyping. Neuroradiologic studies were reviewed. Patients with TFNE were followed every 6 months for the duration of the 3-year study. The frequency of aCL positivity (IgG >20, IgG >40, IgM >7.5) for the 645 patients with TFNE (8.8, 3.1, 4.2%), the 518 persons in the TFNE subgroup with migraine with aura (8.9, 3.3, 4.1%), the 497 persons with migraine without aura (7.0, 2.0, 3.6%), and the 366 control subjects (9.3, 3.6, 3.9%) did not differ significantly between groups. In TFNE patients with elevated aCL titer, the association was positive with diabetes mellitus, TFNE duration <15 minutes, and diplopia and was negative with hemiparesis, tinnitus, and family history of stroke. Findings on imaging consistent with cerebral ischemia were more frequent in aCL-positive persons. The short-term risk of stroke was uniformly low. In young persons, aCL is not associated with migraine or with TFNE, although diabetes mellitus, negative family history of stroke, and brief duration of symptoms (including diplopia) may predict immunoreactivity. Imaging studies suggest an ischemic etiology of TFNE in this cohort.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596001     DOI: 10.1212/wnl.50.5.1433

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Migraine aura pathophysiology: the role of blood vessels and microembolisation.

Authors:  Turgay Dalkara; Ala Nozari; Michael A Moskowitz
Journal:  Lancet Neurol       Date:  2010-03       Impact factor: 44.182

Review 2.  Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies.

Authors:  Mahyar Etminan; Bahi Takkouche; Francisco Caamaño Isorna; Ali Samii
Journal:  BMJ       Date:  2004-12-13

Review 3.  Antiphospholipid antibodies in young adults with stroke.

Authors:  Robin L Brey
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

Review 4.  Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

Review 5.  Neurologic manifestations of the antiphospholipid syndrome.

Authors:  D Tanne; S Hassin-Baer
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 6.  The risk of stroke in patients with migraine and implications for migraine management.

Authors:  Gretchen E Tietjen
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

7.  Anti-beta2-glycoprotein I in Sjogren's syndrome is associated with parkinsonism.

Authors:  Sharon Hassin-Baer; Yair Levy; Pnina Langevitz; Sasson Nakar; Michael Ehrenfeld
Journal:  Clin Rheumatol       Date:  2006-10-21       Impact factor: 2.980

8.  Brain white matter lesions in migraine: what's the meaning?

Authors:  Bruno Colombo; D Dalla Libera; G Comi
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

Review 9.  Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?

Authors:  Mohammad Hassan A Noureldine; Ali A Haydar; Ahmad Berjawi; Rody Elnawar; Ahmad Sweid; Munther A Khamashta; Graham R V Hughes; Imad Uthman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 10.  Neurologic manifestations of the antiphospholipid syndrome.

Authors:  Jose F Roldan; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.